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Abstract 
Fluorescein angiography is an important diagnostic test used for differential diagnosis of retinal disease. 
It is important for the optometric physician to have a working knowledge of the anatomy, pharmacology, 
and the mechanics of this diagnostic procedure. The purpose of this paper is to aid the optometric 
physician in understanding the basic techniques in performing fluorescein angiography. 
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Abstract 
Fluorescein angiography is an important diagnostic 
test used for differential diagnosis of retinal 
disease. It is important for the optometric 
physician to have a working knowledge of the 
anatomy, pharmacology, and the mechanics of this 
diagnostic procedure. The purpose of this paper is 
to aid the optometric physician in understanding 
the basic techniques in performing fluorescein 
angiography. 
(Key words: fluorescein, hypofluorescence, 
hyperfluorescence, RPE (retinal pigmented 
epithelium), retina) 
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Description 
Fluorescein angiography (FA) is a diagnostic photography procedure used to 
detect vascular compromise to the retina, and optic nerve. It may also be used to 
identify areas of the fundus amenable to laser treatment, and to evaluate and monitor 
postlaser success. FA studies the presence and extent of intra, extra, and subretinal 
vasculature alterations that may not be observable ophthalmoscopically or detected 
with other examination techniques. (Posterior Segment Procedures, 1989). 
FA is extremely valuable in studying the normal physiology of the retinal and 
choroidal circulation as well as demonstrating disease processes affecting the 
macula. (Clinical · Ophthalmology, Kanski. 1989) 
Fluorescein 
Fluorescein is a stable, pharmacologically inert vegetable dye. Following 
intravenous injection, 80% of it binds to plasma proteins, mostly albumiil. The 
remaining 20% is free and unbound within the bloodstream and is responsible for 
actual fluorescence during testing. When light energy of 465 to 490 nanometers 
(blue light) is directed at these fluorescein molecules, they fluoresce yellow-green 
with a peak emission of 520 to 530 nm. A f1uorescein camera · ,has a blue .excitation 
filter (such as the Kodak Wratten 47) through which the camera flash passes. The 
resultant blue light continues into the patient's eye, exciting the intraocular free 
fluorescein to its fluorescing nanometer level. These fundus-reflected lights (blue 
and fluorescent yellow-green) return out of the eye through an introduced yellow-
green filter barrier (such as Kodak Wratten G 15 ). This filter absorbs the reflected 
blue light and allows only the emitted fluorescent light to be transmitted and 
recorded on high-speed black-and-white film in the camera. 
Fluorescein's low molecular weight allows it to easily diffuse out of most of the 
body's capillaries, except for the normal vessels of the central nervous system, 
including the retinal vascular endothelium. This diffusion leads to the patient's skin 
becoming jaundiced in appearance for a few hours after testing and the urine 
becoming brilliant yellow for 24 to 48 hours . (Clinical Ophthalmology, Kanski, 1989) 
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Ocular Diseases Indicating the Need for Fluorescein 
Angiography 
Acute posterior multifocal placoid pigment epitheliopathy 
(APMPPE) 
Angiomatosis retinae 
Anterior ischemic optic neuropathy 
Bechet's disease 
Branch retinal vein . occlusion 
Cavernous hemangioma of the retina 
Choroidal rupture (when developing choroidal neovascularization) 
Coat's disease (Retinal Telangiectasia) 
Cystoid maculopathy (Irvine-Gass syndrome) 
Diabetic retinopathy 
Eale' s disease 
Fuch's spot (degenerative myopia) 
Hemicentra! retinal vein occlusion 
Idiopathic central serous choroidopathy 
Iris neovascularization 
Maculopathy of angoid streaks 
Malignant choroidal melanoma 
Preretinal macular fibrosis 
Presumed ocular histoplasmosis (macular changes) 
Proliferative peripheral retinal disease 
Retinal capillary hemangioma 
Retinal macroaneurysm 
Retinal pigment epithelial dystrophies (central) 
Retinal pigment epithelial detachment 
Retinal tumors 
Sensory retinal detachments 
Tumors of the iris and ciliary body 
(Alexander, Larry, Primary Care of the Posterior Se!!ment Disease. 1989.) 
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What to look for: 
Areas of h~[!.o[luorescence caused by 
1. Mechanical blockage from hemorrhage 
2. Exudates 
3. Glial tissue 
4. Pigmentation 
5. Vascular compromise from occlusion 
6. Nonperfusion 
7. Emboli 
8. Arteriosclerosis 
Areas ·of h '¥./l. e r [l u ores c. e.n ~ e due to 
1. Abnormal vasculature 
a. vessel tortuosity 
b. retinal or subretinal neovascularization. 
Examples of abnormal angiograms: 
A. Diabetic Retinopathy 
1. Background Diabetic Retinopathy 
a. Micro aneurysms hyperfl uoresce 
b. Hemorrhages or exudates hypofluoresce 
2. Macular Edema 
a. Fuzzy fluorescence or ground-glass appearance more noticeable in 
later phases indicates dye leakage into macula 
3. Proliferative Diabetic Retinopathy 
a. Abnormally dark areas between retinal vessels indicate areas of 
capillary non-perfusion (hypoxia) 
b. Areas of neovascularization will fill with dye and be well-defined in 
earlier and middle phases . During later phases these areas will 
have a blurry or fuzzy appearance as the dye leaks out into the 
surrounding tissues 
B. Occlusive Vascular Disease . 
1. Retinal Vein Occlusion (Branch and Central) 
a. Venous filling is delayed or does not occur in occluded area 
b. Overlying hemorrhages often obscure the view 
c. Collateral vessels , extra v ascu I ar leakage and edema may also be noted 
2 . Retinal Artery Occlusion (Branch and Central) 
a. Arteriolar phase is delayed or does not occur in occluded area 
b. Venous phases are likewise affected 
c. Generally characterized by non-perfusion 
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C. Age-Related Maculopathy 
1. Atrophic (Dry) ARMD 
a. Drusen hyperfluoresce 
b. Areas of pigment clumping hypofluoresce 
2. Disciform (Wet) ARMD 
a. Sub -retinal (choroidal) neovascular membranes have a 
characteristic early filling during the choroidal phase 
b . Dye continues to leak during later phases 
D. Aphakic Cystoid Macular Edema C Irvine- Class Syndrome) 
1. Macular hyperfluorescence occurs during later arteriovenous phases 
2. Cystic spaces become well -defined during the · late phase showing the 
characteristic "flower petal" pattern 
E. Central Serous Retinopathy 
1. Site of dye leakage usually begins as a small spol of hyperfluorescence in 
the early arteriovenus phase 
2. Fluorescein continues to leak into the overlying sensory retinal 
detachment during later phases , often in a characteristic "smokestack" 
pattern 
(Les Walls, Fluorescein Angiography, handout, 1990) 
Potential side effects and complications: 
1. Nausea 
2. Vomiting 
3. Vasovagal response 
4. Discoloration of skin. urine. etc. 
5. Pain and bruising at injection site 
6. Allergic react.ions 
a) mild - itching, rash 
b) severe- bronchiospasm and anaphylactic shock 
9 
Contraindications to performing a Fluorescein Angiogram 
1. Renal failure 
2. Allergy to fluorescein 
3. History of surgery involving the lymphatics in the arm such as 
mastectomy (IV injection in that arm is contraindicated) 
4. Pregnancy 
(Les Walls, Fluorescein Angio2:raphy, handout, 1990) 
Physiology of the Retina in Relation to the Free 
Circulating Fluorescein 
Inner blood-retinal barrier: 
The tight junctions of the retinal capillary endothelial cells form the inner 
blood-retinal barrier across which neither bound nor · free fluorescein molecules can 
pass. Any leakage from the retinal circulation is therefore pathological. 
Outer (RPE) blood-retinal barrier: 
The major choroidal vessels are impermeable to both bound and free 
fluorescein molecules. On the other hand, the walls of the choriocapillaris are 
extremely thin and contain multiple fenestrations through which free (not bound) 
fluorescein molecules are able to escape into the extravascular space and also across 
Bruch's membrane creating a rei ati vel y uniform fluorescent background during 
testing referred to as the choroidal flush. However, adjacent cells of the RPE are 
firmly attached to each other by a series of adhesions called junctional complexes. 
These complexes (zo~ulae occludentes and zonulae adherentes) prevent the passage 
of free fluorescein molecules across the RPE and maintain the outer blood-retinal 
barrier. Passage of fluorescein across the RPE is therefore abnormal. (Clinical 
Ophthalmology, Kanski, 1989) 
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Circulation of fluorescein: 
Fluorescein is injected- into the median cubital vein and travels up the arm to 
the axillary vein and then to the subclavian where it enters the superior vena cava. 
Then, it travels into the right atrium to the right ventricle. where it proceeds to the 
pulmonary trunk, . through the · lungs and proceeds through the pulmonary veins to 
the left atrium. From that point, it procedes to the left ventricle where it is passed 
through the aorta for systemic circulation. . Fluorescein then travels through either 
the brachiocephalic or left subclavian artery to reach the common carotid arteries 
where it enters the eye through the ophthalmic artery and then passes into the 
choroidal Circulation through the short posterior ciliary arteries. From this point, it 
passes into the retinal circulation through the central retinal artery . Because the 
route to the retinal circulation is slightly longer than that to the choroidal 
circulation, the choroidal vessels are tilled about 1 second before the retina. In the 
choroidal circulation often no precise details are discernible, mainly due to the rapid 
leakage of free fluorescein molecules from the . choriocapillaris and also because the 
melanin in the RPE cells blocks choroidal 1l uorescence. 
Phases of the Angiogram: 
A. Anatomy · 
l. Choroid and choriocapillaris are like a leaky sponge 
2. Normal RPE blocks view of underlying fluorescence 
3. Macular pigment also blocks view somewhat 
B. The normal fluorogram consists of four overlapping phases 
Phase 1 is the pre-arterial phase which begins approximately 8-12 seconds after the 
dye injection, during which the choroidal circulation is filling, but no dye has 
reached the retinal arteries. This is referred to as the choroidal flush. The 
cilioretinal artery, if present, will fill during this stage. 
Phase 2 is the arterial phase which follows 1 to 2 seconds after the pre-arterial 
phase. At this stage the central retinal artery and retinal arterioles fill. This stage 
extends from the first appearance of dye in the arteries until the whole arterial 
circulation is · filled. 
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Phase 3 is the arteriovenous (capillary) phase, which is characterized by complete 
filling of the arteries and capillaries with early lamellar flow in the veins. Both 
arterioles and venules are uniformly filled as dye is being recirculated . 
Pha~e 4 is the venous phase which can be further subdivided into early, mid and 
late stages according to the extent of venous filling and arterial emptying. 
Fluorescence of the arterioles begins to decrease as dye is being eliminated and the 
venules continue to fluorescence. In the late stage only faint residual staining of the 
choroid and retinal vessels remains in a normal eye. 
Materials needed to perform fluorescein angiography: 
1. T -max 400 Black and White film - 36 exposure 
2. 5 ml of 10% fluorescein 
3. Needle, filtration 19g x 1 1/2" 
4. Needle, 23 gauge butterf1y 
5. 5 cc syringe 
6. Alcohol swabs (2) 
7. Small Bandage 
8. Gloves 
9. Blood pressure cuff/ sphygmomanometer/ stethoscope 
10. Tourniquet - reusable 
11. Emesis basin 
12. Dilating drops 
Les Walls, Fluorescein Angiography, handout, 1990 
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Routes of administration: 
1. Intravenous (rapid sequence) fluorescein 
2. Oral fluorescein angiography 
Comparison of routes of administration: 
a. Advantages of IV over oral 
1. Faster 
2. Better detail of choroidal and retinal vasculature (preferred 
technique prior to photocoagulation procedures) 
3. Able to detect choroidal neovascular nets and other anomalies visible 
during the early phases 
b. Advantages of oral over IV 
1. Less likely to cause severe side effects than IV fluorescein 
angiography 
2. May be preferred technique for: 
a) Children 
b) Patients with inaccessible veins 
c) Patients who are very apprehensive about injections 
3. More likely to be performed legally by optometrists at the present 
time 
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RECIPE 
"FLUORESCEIN FLUSH" 
(as opposed to Orange Crush) 
1. Patient should be fasted for 10-12 hours. 
2. Take 1-2 grams of fluorescein solution (for injection) and 
place In non-transparent cup with non-transparent lid 
3. Dilute with a small amount of chilled citrus beverage (Tang, 
diet pop, etc.) 
4. Add small amount of crushed ice 
5. Swirl to mix 
6. Insert drinking straw, and have patient consume entire 
volume of fluorescein preparation within 1-2 minutes. 
7. Examine fundus for evidence of late staining beginning at 10 
to 15 minutes following ingestion 
8. Examine fundus at 15 minute intervals for 60 minutes. 
(Les Walls, Fluorescein Angiography, handout, 1990) 
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Technique for Performing IV (rapid sequence) 
Fluorescein Angiography 
1. Thoroughly discuss the procedure with the patient.. Make sure they understand 
why it is necessary and what the associated risks of the procedure are. 
2. Have the patient sign an informed consent form, indicating their 
understanding. 
3. Dilate pupils as appropriate for the conditions of the individual patient. 
4 . Check the crash cart and oxygen tank to make sure it is operating properly 
(steroids, benadryl, epinephrine . . ). 
5. Fill the syringe from one ampule or vial of injectable 5%,10% or 25% sodium 
fluorescein (10% NaFl is the most often used). 
6. Load one camera back with Kodachrome 64 and one with TMAX 400. 
7 . Take stereo photos or Polaroid photos of each eye on the color setting with the 
red-free filter and the patient's name plate (flash intensity of 18) for auto 
fluorescence. 
8. REMOVE THE NAME PLATE (Otherwise the timer will not show) . 
9. Set the camera for fluorescein photos (flash intensity of 150-200) and take one 
filter test shot. 
10. Prepare the patient for the injection of the fluorescein. 
11. Fasten tourniquet around arm and find appropriate vein 
1. Antecubital area 
2. Back of the hand 
12. Put on gloves. 
13. Clean injection site with alcohol. 
14. Have patient comfortably aligned in camera and set timer to zero . 
· 15. Locate area of regard and adjust the fixation light appropriately. 
16. Insert 23 gauge butterfly needle into vein and watch for blood to enter tubing. 
17 . Attach syringe with NaFI. remove tourniquet and start injecting fluorescein. 
18. Start timer on camera and take the first photo. 
19. The person making the injection. at 1 cc per second, calls out at mid-point and 
when the injection is completed . 
20. When the injection is completed, a second photo is taken. 
21. At the 12 second mark, 1 photo per second is taken for the next 10 seconds- by 
holding the camera button down , the camera will shoot every second. 
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22. At about the 25 second mark, take a photo every 2 seconds for five photos 
23. ~t about the 40 second mark, take a photo every 5 seconds. 
24. At 60 seconds, take a photo of the opposite eye for two shots. 
25. At 70 seconds, take a photo every 5 seconds of the target eye. 
26. At 120 seconds, take a photo of the opposite eye. 
27. At 150 seconds, take a photo of the target eye and continue every 10 seconds. 
28. At 180 seconds, take one shot every 30 seconds to one minute. 
29. At 300 seconds, take two shots of the targeted eye and two of the opposite eye. 
30. At 10 minutes take two more shots of each eye - if necessary. 
31. Have the patient rest for twenty minutes following the procedure, again telling 
him/her about the discoloration of the skin and urine - if necessary. 
(Les Walls, Fluorescein Angio~Uaphy, handout, 1990) 
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Treatment of Anaphylaxis 
1. Place patient in recumbent position and elevate lower extremities 
2. Monitor vital signs often (every three minutes) 
3. Apply tourniquet proximal to site of antigen injection : remove every 10 to 15 
minutes. 
4. Administer aqueous epinephrine 1:1000 into non occluded site 
Adults: 0.3 - 0.5 mL SC or IM 
Children: 0.01 mLI kg, SC or IM q 15 min em 
5. Administer epinephrine 1:1000 into site of antigen injection 
Adults : 0.15 - 0.25 mL SC 
Children: 0.005 mL/kg, SC 
6. Establish and maintain. airway with cropharyngeal airway device, endotracheal 
intubation, transtracheal catherterization, or cricothyrotomy 
7. Administer oxygen at 6-10 Llmin In office 
In E.R. 
8. Institute rapid fluid replacement with saline or colloid solution 
9. If hypertension is present 
Adults or children: dopamine (Dopastat, Intropin), 2:10 um/kg/min, or 
Adults: norepinephrine (Levophed), 8mg/500 mL dextrose (5%) in saline at 
2mL/min and adjust rate to maintain low-normal blood pressure 
10. If refractory hypotension is present: 
Cimetidine (tagamet), 300 mg, or ranitidine (Zantac), 50mg, IV, over 3 to 5 min 
11. If bronchiospasm is present: 
Aminophyline, 6mg/kg, IV, over 20 min 
12. To block late-phase reaction: 
Hydrocortisone sodium succinate (A-hydroCort, Solu-Cort), 100 mg, IV push, 
and 100 mg dextrose (5%) in saline, IV, q2-q4h 
13. To block H, receptors: 
Diphenhydramine (Benadryl) . 1-2 mg/kg, IV. up to 50 mg over 3 min 
14. For adults taking a beta-adrenergic blocker 
Atropine, 0.5 mg, IV, q5min until heart rate is 60 beats/min, or Isoproterenol 
(lsuprel) drip 2-20 ug/min titrated to heart rate of 60 beats/min , or glucagon, 
0.05 mg/kg· bolus, IV, followed by 0.07 mg/kg/hr continuous IV infusion. 
Les Walls , Fluorescein Anf;iography, handout, 1990 
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Reactions to Fluorescein and Treatment 
Side Effects and Complications 
1. Nausea & Vomiting 
2. Fainting and syncopy 
(usually vasovagal; occurs 
more frequently in 
diabetic patients 
3. Painful local extravasation 
4. Generalized skin eruption 
(urticaria, pruitus) 
5. Bronchiospasrn and anaphylaxis 
(Acute medical emergency) 
Treatrnen t 
L Time and reassurance; have patient breathe 
through mouth · slowly and deeply; reaction 
passes quickly 
2. For those patients who have experienced 
nausea and vomiting from previous 
f1uorescein injection , perform test in 
fasting state and give 25 to 50mg of 
Phenergan by mouth 1 hour before 
angicigraphy 
Time and reassurance; further treatment is 
rarely necessary 
2. Monitor pulse and blood pressure 
3. Smelling salts 
4. Oxygen 
5. If severe. supine position and life-support 
measures. 
I. Icc pack to site of injection 
2 Subcutaneous local anesthetic, rarely 
nece s sary 
1. Intravenous administration of 
antihistimine (Benadryl 25 to 50 mg) 
1. Provision of airway 
2. Oxygenation 
3. Close monitoring of vital signs 
4 . Systemic medications as needed 
a. Epinephrine 
b. Steroids 
c. Antihistamines 
d. Pressor agents; levarterenol 
(Levophed). metaraminol (Aramine) 
bitartrate 
e. Aminophylline 
(Les Walls, Fluorescein Angioe:raphy, handout, 1990) 
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Management of Persons Exposed to Blood 
Once an exposure has occurred, the blood of the individual from whom exposure occurred should 
be tested for hepatitis B surface antigen (HBsAg) and antibody to human immunodeficiency virus 
(HIV antibody) . Local laws regarding consent for testing source individuals should bet followed. 
Testing of the source individual should be done at a location where appropriate pretest counseling 
is available ; post-test counseling and referral for treatment should be provided. 
Human Immunodeficiency Virus Post-exposut·e Management 
IF 
The source individual 
has AIDS 
OR 
The source individual is 
positive for HIV 
infection 
OR 
The source individual 
refuses to be tested 
The source individual is 
tested and found 
seronegative 
The source individual 
cannot be identified 
THEN 
l. 1l1e exposed worker should be 
counseled about the risk of infection. 
2. The exposed worker should be 
evaluated clinically and serologically 
for evidence of HIV infection as soon as 
possible after the exposure . 
3. The exposed worker should be 
advised to report and seek medical 
evaluation for any febrile illness that 
occurs within 12 weeks after the 
exposure . 
4. The exposed worker should be 
advised to refrain form blood donation 
and to use appropriate protection 
during sexual intercourse during the 
follow-up period , especially the first 6 
- 12 weeks after exposure. 
Baseline testing of the exposed worker 
with follow-up testing 12 weeks later 
may be performed if desired by the 
worker or recommended by the worker's 
health care provider. 
Decisions regarding appropriate 
follow-up should be indivi dualized . 
Serologic testing should be done if the 
worker is concerned that HIV 
transmission has occ urred . 
AND 
An exposed worker who 
tests negative initially 
should be retested 6 weeks, 
12 weeks, and 6 months 
after exposure to .determine 
whether transmission has 
occurred. 
l. Being "exposed to blood" means having bl ood, blood-contaminated saliva, or a blood-
contaminated object come into contact wi th broken skin or mucous membranes, or pierce the skin 
as through a needlestick injury . 
2. The information given in this table is based on recommendations in Guidelines for Prevention 
of Transmission of HJV and HBV to Health-Care and Public-Sqf'ety Workers. DHHS (NIOSH) 
Publication No. 89-107; Cincinnati, Ohio, February 1989. 
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Management of Persons Exposed to Hepatitis B 
Once an exposure has occurred, the blood of the individual from whom exposure occurred should 
be tested for hepatitis B surface antigen (HBsAg) and antibody to human immunodeficiency virus 
(HIV antibody). Local laws regarding cons-ent for testing source individuals should be followed. 
Testing of the source individual should be done at a location where appropriate pretest counseling 
is available; posttest counseling and referral for treatment should be provided. 
IF 
The source individual 
found positive for 
HBsAg 
The source individual 
found negative for 
HBsAg 
AND 
is The exposed worker has not 
been vaccinated against 
hepatitis B. 
The exposed worker has 
been vaccinated against 
hepatitis B. 
is The exposed worker has not 
been vaccinated against 
hepatitis B. 
The exposed worker has 
been vaccinated against 
hepatitis B . 
1HEN 
I . The worker should receive the 
vaccine series for hepa titis B. 
2. The worker should receive a single 
dose of hepatitis B immune globulin if 
it can be given within 7 days of 
exposure. 
The exposed worker should be tested 
for antibody to hepatitis B surface 
an tigen (anti-HBs), and given one dose 
of vaccine and one dose of HBIG if the 
antibody leve l in the worker's blood 
sample is inadequate (i.e., <10 SRU by 
RIA, negative by EIA) 
The worker should be encouraged to 
receive hepatitis B vaccine. 
No further action is needed. 
The source individual The exposed worker has not 1. The worker should receive the 
refuses testin g or cannot been vacc inated against 
be identified hepatitis B. 
The exposed worker has 
been vaccinated against 
hepatitis B. 
1. Being "exposed to blood" means having blood, 
contaminated object come into contact with broken 
as through a needles tick injury. 
hepntitis B series. 
2. HBIG administration should be 
considered on an individual basis when 
the source individual is known or 
suspected to be at high risk of HBV 
infection. 
Management and treatment of the 
exposed worker should be 
individualized. 
blood-contaminated saliva, or a blood-
skin or mucous membranes, or pierce the skin 
2. The information given in this table is based on recommendations in Guidelines for Prevention 
of Transmission of HIV and HBV to Health-Care and Public-Sq{ery Workers. DHHS (NIOSH) 
Publication No. 89-107; Cincinnati, Ohio , February 1989. 
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